IN2014MN02002A - - Google Patents

Info

Publication number
IN2014MN02002A
IN2014MN02002A IN2002MUN2014A IN2014MN02002A IN 2014MN02002 A IN2014MN02002 A IN 2014MN02002A IN 2002MUN2014 A IN2002MUN2014 A IN 2002MUN2014A IN 2014MN02002 A IN2014MN02002 A IN 2014MN02002A
Authority
IN
India
Prior art keywords
organic compound
sugar
nanopowder
compound
less
Prior art date
Application number
Other languages
English (en)
Inventor
Takahiro Tada
Kazuhiro Kagami
Shiro Yokota
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of IN2014MN02002A publication Critical patent/IN2014MN02002A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members
    • B02C17/205—Adding disintegrating members to the tumbling mill
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/06—Selection or use of additives to aid disintegrating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
IN2002MUN2014 2012-05-11 2013-05-11 IN2014MN02002A (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012108972 2012-05-11
PCT/JP2013/003023 WO2013168437A1 (ja) 2012-05-11 2013-05-11 有機化合物ナノ粉体、その製造方法ならびに懸濁液

Publications (1)

Publication Number Publication Date
IN2014MN02002A true IN2014MN02002A (no) 2015-08-07

Family

ID=49550500

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2002MUN2014 IN2014MN02002A (no) 2012-05-11 2013-05-11

Country Status (17)

Country Link
US (1) US9278071B2 (no)
EP (1) EP2848243B1 (no)
JP (1) JP6054380B2 (no)
KR (1) KR101772263B1 (no)
CN (1) CN104203217B (no)
AU (1) AU2013259150B2 (no)
BR (1) BR112014028431B1 (no)
CA (1) CA2867236C (no)
ES (1) ES2952419T3 (no)
IL (1) IL234327B (no)
IN (1) IN2014MN02002A (no)
MX (1) MX341663B (no)
PL (1) PL2848243T3 (no)
PT (1) PT2848243T (no)
RU (1) RU2613109C2 (no)
TW (1) TWI579004B (no)
WO (1) WO2013168437A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105658203B (zh) * 2013-11-08 2021-03-16 株式会社活效制药 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂
DK3102185T3 (da) 2014-02-03 2021-10-04 Apurano Pharmaceuticals Gmbh Nanosuspension af naturlige materialer og fremgangsmåde til fremstilling deraf
JPWO2015137289A1 (ja) * 2014-03-10 2017-04-06 国立大学法人 東京大学 水分散性非晶質粒子及びその調製方法
EP3721868B1 (en) * 2015-01-26 2022-06-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
JP6612081B2 (ja) * 2015-07-31 2019-11-27 東洋精糖株式会社 α−グルコシルルチン含有プテリジン誘導体ナノ粒子の製造方法およびα−グルコシルルチン含有プテリジン誘導体ナノ粒子
RU2710952C2 (ru) * 2015-08-04 2020-01-14 Апурано Лайф Сайенсис Гмбх Наносуспензия, содержащая частицы и экстракт природных материалов
CZ307916B6 (cs) * 2017-05-08 2019-08-21 mcePharma s. r. o. Orodispergovatelná tableta s biodostupným kurkuminem a její použití
CN111253498B (zh) * 2020-03-10 2021-11-09 中国科学院海洋研究所 一种褐藻多糖衍生物纳米胶束的制备
CA3178769A1 (en) 2020-05-18 2021-11-25 Jonas Savmarker New pharmaceutical composition for drug delivery
CN113209031A (zh) 2021-04-30 2021-08-06 青岛农业大学 一种负载两性霉素B与β-1，3-葡聚糖酶的双靶向复合纳米体系及其制备方法、应用
CN113620937A (zh) * 2021-08-03 2021-11-09 湖南复瑞生物医药技术有限责任公司 一种高纯度小粒径普仑司特的制备方法
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
ATE424811T1 (de) * 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
JP2006089386A (ja) 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
WO2010032434A1 (ja) 2008-09-19 2010-03-25 株式会社アクティバスファーマ 医療用複合有機化合物粉体、その製造方法ならびに懸濁液
KR101834940B1 (ko) 2010-03-22 2018-03-06 (주)바이오시네틱스 나노입자 제조방법

Also Published As

Publication number Publication date
CN104203217B (zh) 2017-02-15
BR112014028431B1 (pt) 2022-01-11
WO2013168437A1 (ja) 2013-11-14
TWI579004B (zh) 2017-04-21
EP2848243B1 (en) 2023-07-12
AU2013259150A1 (en) 2014-08-28
AU2013259150B2 (en) 2016-07-14
CA2867236C (en) 2017-02-28
JP6054380B2 (ja) 2016-12-27
EP2848243A1 (en) 2015-03-18
EP2848243A4 (en) 2015-12-23
US9278071B2 (en) 2016-03-08
ES2952419T3 (es) 2023-10-31
MX341663B (es) 2016-08-30
RU2014148792A (ru) 2016-06-27
IL234327B (en) 2018-06-28
PL2848243T3 (pl) 2024-04-08
CN104203217A (zh) 2014-12-10
US20140328917A1 (en) 2014-11-06
KR101772263B1 (ko) 2017-08-28
JPWO2013168437A1 (ja) 2016-01-07
BR112014028431A2 (pt) 2017-06-27
PT2848243T (pt) 2023-08-02
MX2014010772A (es) 2014-10-14
CA2867236A1 (en) 2013-11-14
RU2613109C2 (ru) 2017-03-15
TW201400142A (zh) 2014-01-01
KR20150008376A (ko) 2015-01-22

Similar Documents

Publication Publication Date Title
IN2014MN02002A (no)
MX2013009496A (es) Composicion y metodo para retirar la torta de filtro.
AU2016216707A1 (en) Blue-colored gold nanoparticles for immunological measurement, process for production of same, and measurement method using same
WO2012051426A3 (en) Aggregate nanoparticulate medicament formulations, manufacture and use thereof
MX2013004096A (es) Productos organopolisiloxanos granulado.
EA201591036A1 (ru) Высокочистый порошок, предназначенный для термического напыления
MX360762B (es) Partículas híbridas de carbono de superficie modificada, métodos de realización y aplicaciones de las mismas.
MY160470A (en) Process for producing polishing liquid composition
MX2013010697A (es) Composicion de recubrimiento a base de alquídico.
WO2011008064A3 (ko) 양자점 함유 입자 및 이의 제조 방법
MX367283B (es) Particula nanoestructurada autoensamblada y metodo para su preparacion.
MY166560A (en) Ddr zeolite seed crystal, method for producing same, and method for producing ddr zeolite membrane
WO2009111437A3 (en) Monodispersed organic monolayer coated calcium-containing nanoparticles
MX353387B (es) Proceso novedoso para la preparación de sílices precipitadas que tienen una morfología específica, un tamaño de partícula específico y una porosidad específica.
PH12015502003A1 (en) Ophthalmic formulations
EA201490181A1 (ru) Способ получения мелких частиц безводных кристаллов b арипипразола
WO2010004163A3 (fr) Suspension colloidale generatrice d'hydrogene
MY167230A (en) Water-dispersed pressure-sensitive adhesive composition and method for producing same
EA201590670A1 (ru) Частицы для доставки полезных веществ, композиции, содержащие указанные частицы, и способ обработки субстратов
MX352763B (es) Auxiliar analitico con recubrimiento hidrofilico que contiene nanoparticulas con estructura de silice.
WO2013020701A3 (en) Agglomerating magnetic alkoxysilane-coated nanoparticles
WO2014052074A3 (en) Coatable composition, photocatalytic articles, and methods of making the same
WO2011052940A3 (ko) 클로피도그랠 황산수소염 ⅰ형 제조방법
CN103804720A (zh) 磁性羧甲基化壳聚糖纳米粒子的制备方法
WO2012168948A3 (en) Process for febuxostat